Literature DB >> 17438108

HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions.

Shiwen Peng1, Cornelia Trimble, Lee Wu, Drew Pardoll, Richard Roden, Chien-Fu Hung, T-C Wu.   

Abstract

PURPOSE: The fact that up to 30% of established high-grade squamous intraepithelial lesions (HSIL) of the cervix regress spontaneously presents the opportunity to identify clinically relevant human papillomavirus (HPV) viral epitopes associated with disease outcome. Two human HPV antigens, E6 and E7, are functionally required for initiation and maintenance of cervical cancer precursor lesions and invasive cervical cancer. The identification and characterization of endogenously processed HPV antigenic epitopes in closely characterized patient cohorts will provide insight into the reasons for success or failure of therapeutic approaches. EXPERIMENTAL
DESIGN: We characterized the HPV-16 E6/E7-specific T-cell epitopes using E6/E7 overlapping peptide pools with peripheral blood lymphocytes obtained from normal healthy donors. We then analyzed the difference in the HPV-16 T-cell immune responses in HPV-16+ HSIL patients with or without spontaneous regression of lesions using the statistical methods.
RESULTS: We have identified an HPV-16 E7-specific CD4+ T-cell epitope [amino acids (aa) 71-85] that was restricted by HLA-DQB1*0201. Analysis of peripheral blood lymphocytes obtained from 14 HLA-DQB1*02 patients with HPV-16+ HSILs showed that the HPV-16+ E7 peptide (aa 71-85)-specific CD4+ T-cell immune response was significantly higher in the group of patients with regression compared with the patients without regression (P value <0.05).
CONCLUSIONS: The HPV-16 E7 peptide-specific CD4+ T-cell immune response correlates with spontaneous regression of established HPV16+ HSILs. Thus, this E7 epitope may be useful for the characterization of HPV-specific immune responses in patients infected with HPV-16 or immunized with HPV vaccines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17438108      PMCID: PMC3181117          DOI: 10.1158/1078-0432.CCR-06-2916

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  23 in total

1.  Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects.

Authors:  Annemieke de Jong; Sjoerd H van der Burg; Kitty M C Kwappenberg; Jeanette M van der Hulst; Kees L M C Franken; Annemieke Geluk; Krista E van Meijgaarden; Jan Wouter Drijfhout; Gemma Kenter; Pieter Vermeij; Cornelis J M Melief; Rienk Offringa
Journal:  Cancer Res       Date:  2002-01-15       Impact factor: 12.701

Review 2.  Exposing the immunology of naked DNA vaccines.

Authors:  D M Pardoll; A M Beckerleg
Journal:  Immunity       Date:  1995-08       Impact factor: 31.745

Review 3.  DNA vaccines.

Authors:  H L Robinson; C A Torres
Journal:  Semin Immunol       Date:  1997-10       Impact factor: 11.130

Review 4.  DNA vaccines.

Authors:  J J Donnelly; J B Ulmer; J W Shiver; M A Liu
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

Review 5.  HPV DNA vaccines.

Authors:  Michelle Moniz; Morris Ling; Chien-Fu Hung; T-C Wu
Journal:  Front Biosci       Date:  2003-01-01

6.  Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide.

Authors:  Anna S Kadish; Patrick Timmins; Yuexian Wang; Gloria Y F Ho; Robert D Burk; John Ketz; Wu He; Seymour L Romney; Anne Johnson; Ruth Angeletti; Maria Abadi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-05       Impact factor: 4.254

Review 7.  Vaccination to prevent and treat cervical cancer.

Authors:  Richard B S Roden; Morris Ling; T-C Wu
Journal:  Hum Pathol       Date:  2004-08       Impact factor: 3.466

8.  Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6.

Authors:  Annemieke de Jong; Mariëtte I E van Poelgeest; Jeanette M van der Hulst; Jan Wouter Drijfhout; Gert Jan Fleuren; Cornelis J M Melief; Gemma Kenter; Rienk Offringa; Sjoerd H van der Burg
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

9.  Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group.

Authors:  F X Bosch; M M Manos; N Muñoz; M Sherman; A M Jansen; J Peto; M H Schiffman; V Moreno; R Kurman; K V Shah
Journal:  J Natl Cancer Inst       Date:  1995-06-07       Impact factor: 13.506

10.  Disease-stage variance in functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes.

Authors:  Dominic E Warrino; Walter C Olson; William T Knapp; Meera I Scarrow; Lori J D'Ambrosio-Brennan; Richard S Guido; Robert P Edwards; W Martin Kast; Walter J Storkus
Journal:  Clin Cancer Res       Date:  2004-05-15       Impact factor: 12.531

View more
  30 in total

1.  Absence of γ-Chain in Keratinocytes Alters Chemokine Secretion, Resulting in Reduced Immune Cell Recruitment.

Authors:  Karolin Nowak; Daniela Linzner; Adrian J Thrasher; Paul F Lambert; Wei-Li Di; Siobhan O Burns
Journal:  J Invest Dermatol       Date:  2017-06-17       Impact factor: 8.551

Review 2.  HPV Vaccines: today and in the Future.

Authors:  Anna-Barbara Moscicki
Journal:  J Adolesc Health       Date:  2008-10       Impact factor: 5.012

3.  Antigen design enhances the immunogenicity of Semliki Forest virus-based therapeutic human papillomavirus vaccines.

Authors:  P P Ip; A Boerma; M Walczak; K Oosterhuis; J B Haanen; T N Schumacher; H W Nijman; T Daemen
Journal:  Gene Ther       Date:  2015-03-26       Impact factor: 5.250

4.  Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses.

Authors:  Mark L Bagarazzi; Jian Yan; Matthew P Morrow; David B Weiner; Niranjan Y Sardesai; Xuefei Shen; R Lamar Parker; Jessica C Lee; Mary Giffear; Panyupa Pankhong; Amir S Khan; Kate E Broderick; Christine Knott; Feng Lin; Jean D Boyer; Ruxandra Draghia-Akli; C Jo White; J Joseph Kim
Journal:  Sci Transl Med       Date:  2012-10-10       Impact factor: 17.956

5.  A Genome-Wide Association Study Identifies Two Novel Susceptible Regions for Squamous Cell Carcinoma of the Head and Neck.

Authors:  Hongliang Liu; Jian Wang; Robert Yu; Sanjay Shete; Erich M Sturgis; Guojun Li; Kristina R Dahlstrom; Zhensheng Liu; Christopher I Amos; Qingyi Wei
Journal:  Cancer Res       Date:  2020-04-10       Impact factor: 12.701

6.  CD4+ T cells against human papillomavirus-18 E7 in patients with high-grade cervical lesions associate with the absence of the virus in the cervix.

Authors:  Samantha Seresini; Massimo Origoni; Luigi Caputo; Flavia Lillo; Renato Longhi; Simone Vantini; Anna Maria Paganoni; Maria Pia Protti
Journal:  Immunology       Date:  2010-06-02       Impact factor: 7.397

7.  Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia.

Authors:  Wen Yang; Yan Song; Yun-Long Lu; Jun-Zhong Sun; Hong-Wei Wang
Journal:  Immunology       Date:  2013-08       Impact factor: 7.397

8.  Enhancement of tumor-specific T cell-mediated immunity in dendritic cell-based vaccines by Mycobacterium tuberculosis heat shock protein X.

Authors:  In Duk Jung; Sung Jae Shin; Min-Goo Lee; Tae Heung Kang; Hee Dong Han; Seung Jun Lee; Woo Sik Kim; Hong Min Kim; Won Sun Park; Han Wool Kim; Cheol-Heui Yun; Eun Kyung Lee; T-C Wu; Yeong-Min Park
Journal:  J Immunol       Date:  2014-07-02       Impact factor: 5.422

9.  Human papillomavirus 16-specific T cell responses in classic HPV-related vulvar intra-epithelial neoplasia. Determination of strongly immunogenic regions from E6 and E7 proteins.

Authors:  I Bourgault Villada; M Moyal Barracco; S Berville; M L Bafounta; C Longvert; V Prémel; P Villefroy; E Jullian; T Clerici; B Paniel; B Maillère; J Choppin; J G Guillet
Journal:  Clin Exp Immunol       Date:  2009-07-30       Impact factor: 4.330

10.  Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions.

Authors:  Trinidad Garcia-Iglesias; Alicia Del Toro-Arreola; Benibelks Albarran-Somoza; Susana Del Toro-Arreola; Pedro E Sanchez-Hernandez; Maria Guadalupe Ramirez-Dueñas; Luz Ma Adriana Balderas-Peña; Alejandro Bravo-Cuellar; Pablo C Ortiz-Lazareno; Adrian Daneri-Navarro
Journal:  BMC Cancer       Date:  2009-06-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.